drugset / Trial / NCT06967259
ENA-001 for Opioid Induced Respiratory Depression
Phase 1
Recruiting
36 enrolled
Enalare Therapeutics Inc.
National Institute on Drug Abuse (NIDA) · collab
RandomizedSequentialQuadruple-blindTreatment
Summary
This study is a Phase I clinical trial to assess the safety, tolerability, and pharmacokinetic (PK) and pharmacodynamic (PD) profiles with single intravenous (IV) and intramuscular (IM) doses of ENA-001.
Timeline
- Start
- 2025-05-14
- Primary completion
- 2026-07-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ENA-001 | Small molecule | — | Intravenous |